In the ongoing battle against eczema, a skin condition that plagues millions with dry, itchy, and inflamed skin, a ray of hope shines from the laboratories of New York Medical. A recent study spearheaded by postdoctoral fellow Anish R. Maskey, Ph.D., has brought to light the promising effects of berberine, a natural compound, in the fight against eczema exacerbated by the bacterium Staphylococcus aureus.
Eczema sufferers are all too familiar with the temporary relief that topical antibiotics provide, only to be overshadowed by the looming threat of antibiotic resistance. Moreover, the use of steroids carries the risk of topical steroid withdrawal (TSW) syndrome. However, Maskey’s research, presented at ASM Microbe, offers a glimpse into a future where eczema can be managed more effectively without these adverse effects.
